Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: (A) Anti-S1 IgG in serum measured by a microarray-based immunoassay, (B) serum pseudovirus neutralization against the Delta VOC two and six months after vaccination measured by pNT, and (C) SARS-CoV-2 S1 specific T cell response detected by IGRA. Dotted horizontal lines indicate themanufacturer’s threshold for anti-S1 IgG ≥1 S/Co (A) and the lower limit of detection (1:10 dilution) for pNT (B). Horizontal lines within plotted data regions indicate the median and interquartile range, except for pNT, where the geometric mean and 95% confidence interval is shown. P values (all <0.0001) were calculated by non-parametric Mann Whitney U test. S/Co: signal-to-cutoff, pNT: pseudovirus neutralization test, ID 50 : 50% inhibition dilution, IGRA: interferon-γ release assay, IU: international units.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Microarray, Neutralization, MANN-WHITNEY, Inhibition, Release Assay

Journal: medRxiv

Article Title: Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

doi: 10.1101/2021.08.26.21262468

Figure Lengend Snippet: ( A ) Anti-SARS-CoV-2 N, ( B ) RBD- ( C ) and full-spike IgG measured in the serum of BNT162b2 vaccinated HCW and elderly persons six months after the first vaccination. ( D ) Neutralizing capacity was measured by sVNT and ( E ) serum neutralization against Alpha (B.1.1.7) VOC detected by pNT in vaccinated HCW and elderly persons six months after the first vaccination. ( F ) Binding capacity of serum IgG against six different RBDs of SARS-CoV-2 variants carrying the indicated mutations in HCW and elderly, measured by ELISA. Dotted lines indicate the manufacturer’s threshold values: for anti-N, anti-RBD, and anti-full spike IgG ≥1 S/Co, for sVNT >30%, and the lower limit of detection (1:10 dilution) for pNT. Lines indicate the median and interquartile range except for pNT, where the geometric mean and 95% confidence interval are shown. P values were calculated by the non-parametric Mann Whitney U test or Kruskal-Wallis test with Dunn’s multiple comparisons test. S/Co: signal-to-cutoff, N: nucleocapsid protein, RBD: receptor-binding domain, sVNT: surrogate virus neutralization test, ACE2: angiotensin-converting enzyme 2, ID50: 50% inhibition dilution.

Article Snippet: Functional neutralization capacity was investigated using a commercially available ELISA-based SARS-CoV-2 RBD-ACE2 binding inhibition assay (surrogate SARS-CoV-2 neutralization test (sVNT) cPass (medac GmbH, https://international.medac.de ).

Techniques: Neutralization, Binding Assay, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Inhibition

Journal: Viruses

Article Title: Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants

doi: 10.3390/v14020230

Figure Lengend Snippet: Analysis of mAb 9G8 blocking the SARS-CoV-2 spike RBD variant from binding to the human ACE2 receptor by surrogate virus neutralization test (sVNT). The percent inhibition of mAb 9G8 was measured against RBD of SARS-CoV-2 WT or SARS-CoV-2 variants such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), Delta Plus/AY.1 (B.1.617.2.1), and Epsilon (B.1.429/7). The mAb 6C8 specific for nucleocapsid protein was used as a negative control. The results were expressed as the arithmetic mean of percent-blocking values of triplicates and ±SD of the mean.

Article Snippet: To determine the neutralizing activity of mAbs against SARS-CoV-2 variants, a GenScript cPASS surrogate virus neutralization test (sVNT) was performed according to manufacturer’s instructions (GenScript, Piscataway, NJ, USA).

Techniques: Blocking Assay, Variant Assay, Binding Assay, Virus, Neutralization, Inhibition, Negative Control

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques: Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: The RBD-targeting semi-quantitative kits showed high sensitivity: GenScript cPass sVNT (94.68%), Roche Elecsys Anti-SARS-CoV-2 S (96.68%), and Abbott SARS-CoV-2 IgG II Quant (97.67%).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques: Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: The ROC AUCs for the prediction of PRNT ND 50 ≥ 20 of the GenScript cPass sVNT, Roche Elecsys Anti-SARS-CoV-2, Roche Elecsys Anti-SARS-CoV-2 S, and Abbott SARS-CoV-2 IgG II Quant kits were 0.941, 0.916, 0.950, and 0.964, respectively ( ).

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: Although GenScript cPass sVNT kit exhibited a lower Pearson’s correlation coefficient than the Abbott AdviseDx SARS-CoV-2 IgG II, this may be due to the narrower reportable range of GenScript cPass sVNT, leading to early saturation in subjects with high antibody titers.

Techniques: Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: Although GenScript cPass sVNT kit exhibited a lower Pearson’s correlation coefficient than the Abbott AdviseDx SARS-CoV-2 IgG II, this may be due to the narrower reportable range of GenScript cPass sVNT, leading to early saturation in subjects with high antibody titers.

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: Although GenScript cPass sVNT kit exhibited a lower Pearson’s correlation coefficient than the Abbott AdviseDx SARS-CoV-2 IgG II, this may be due to the narrower reportable range of GenScript cPass sVNT, leading to early saturation in subjects with high antibody titers.

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: Although GenScript cPass sVNT kit exhibited a lower Pearson’s correlation coefficient than the Abbott AdviseDx SARS-CoV-2 IgG II, this may be due to the narrower reportable range of GenScript cPass sVNT, leading to early saturation in subjects with high antibody titers.

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: Although GenScript cPass sVNT kit exhibited a lower Pearson’s correlation coefficient than the Abbott AdviseDx SARS-CoV-2 IgG II, this may be due to the narrower reportable range of GenScript cPass sVNT, leading to early saturation in subjects with high antibody titers.

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: Although GenScript cPass sVNT kit exhibited a lower Pearson’s correlation coefficient than the Abbott AdviseDx SARS-CoV-2 IgG II, this may be due to the narrower reportable range of GenScript cPass sVNT, leading to early saturation in subjects with high antibody titers.

Techniques:

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: SARS-CoV-2 exposure in wild white-tailed deer ( Odocoileus virginianus )

doi: 10.1073/pnas.2114828118

Figure Lengend Snippet: Boxplot of SARS-CoV-2 serological results for WTD tested with the Genscript cPass sVNT. Boxes outline the interquartile range, which is the range of the middle 50% of values, horizontal bars are medians, and dots are individual sample results.

Article Snippet: Antibodies to SARS-CoV-2 were detected in 40% of 2021 samples ( ) screened with a commercially available surrogate virus neutralization test (sVNT, Genscript cPass).

Techniques: